• Novartis unit Sandoz Canada won Health Canada clearance for (Pr)Sandoz Semaglutide, a generic version of Novo Nordisk’s Ozempic.
• Label covers once-weekly treatment of type 2 diabetes in adults to improve glycemic control alongside lifestyle measures or other antidiabetic drugs.
• Authorization spans 0.25 mg, 0.5 mg, 1 mg subcutaneous doses via two prefilled pen presentations.
• Sandoz Canada is preparing for a future commercial launch, targeting improved access amid rising Canadian demand for semaglutide pens.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via CNW (Ref. ID: 202609180742CANADANWCANADAPF_C6165) on September 18, 2026, and is solely responsible for the information contained therein.